The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

In March 2023, Grifols announced a collaboration with Selagine, a spin-out company from the University of Illinois at Chicago (UIC) that focuses on novel therapeutics for eye diseases, to develop ...

Shares in Spanish pharma group Grifols have plummeted after UK-based hedge fund Gotham City Research issued a report claiming it has fraudulently manipulated its financial reporting by not ...

Brookfield still hasn't managed to obtain the €9.5 billion of bank financing to repay Grifols’ debt, nor the €3.5 billion it ...

to back the take-private of Spanish pharmaceutical producer Grifols SA. Lenders are preparing to send final proposals next week, with the expectation that a bank group will be appointed by the end ...

Grifols' (NASDAQ:GRFS) ADRs gained on Thursday after Bloomberg News reported that several banks are finalizing offers to back nearly €11B ($11.6B) debt package that Brookfield Asset Management ...

Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. Shares traded 4.7% ...

European shares struggle ahead of speeches from ECB policymakers 9:30 AM UTC Canadian fund Brookfield plans to offer about 7 billion euros ($7.4 billion) for Spanish drugmaker Grifols after ...

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasis Grifols surgical bleeding management ...